GlycoEra completes CHF 45m Series A Financing Round. The advisors

GlycoEra has successfully completed a CHF 45 million Series A financing round, co-led by 5AM Ventures, Roche Venture Fund and Sofinnova Partners. LimmaTech Biologics, from which GlycoEra was spun-out, also participated in this round.

GlycoEra’s innovative CustomGlycan platform unlocks the power of glycan-mediated biology to develop a pipeline of novel biologics for a broad range of indications.

Proceeds from the financing will be used to support the growth of the company and to demonstrate the breadth and value of its CustomGlycan Platform technology in developing assets that can unlock unique biological activities for therapeutic targets in several disease indications.

The advisors

Walder Wyss partner Alexander Gutmans

Vischer has been acting as legal counsel to GlycoEra since inception including the spin-out and the current financing. The team is led by partner Matthias Staehelin (pictured top) and includes associate Pauline Pfirter and associate Timothy Woodtli (all corporate/m&a) 

Walder Wyss advised 5AM Ventures, Roche Venture Fund and Sofinnova Partners as lead investors on this transaction. The Walder Wyss team was led by Alexander Gutmans (partner, corporate/m&a and venture capital, pictured left) and included Michelle Bruni (senior associate, corporate/m&a and tax), Karina Tschon (associate, corporate/m&a and venture capital) and Lena Götzinger (associate, IP/IT and licensing).

FabioAdmin

SHARE